Streetbeat News

HKMPF

Hikma Pharmaceuticals Plc

https://www.hikma.com/

CEO

Sigurdur Olafsson

Industry

Medicinal and Botanical Manufacturing

Open

25.66

Mkt cap

5.3B

Volume

High

25.66

P/E Ratio

28.31

52-wk high

26.50

Low

24.06

Div yield

0.03

52-wk low

21.90

The DEA has authorized a 24% increase in production limits for Takeda's Vyvanse to address the ADHD medication shortage in the U.S. and meet international demand. This move follows the FDA's request and aims to stabilize supply amid rising demand and manufacturing delays.

Portfolio Pulse from Vandana Singh

September 06, 2024 | 1:46 pm

Jazz Pharmaceuticals and Hikma Pharmaceuticals are facing allegations of delaying a generic version of Jazz's narcolepsy drug, Xyrem, to maintain high prices. The case will proceed to trial, with claims of antitrust violations and price increases. Jazz denies the allegations, citing regulatory approval of its distribution strategy.

Portfolio Pulse from Vandana Singh

August 28, 2024 | 5:37 pm

The FDA is seeking new suppliers for methotrexate, a cancer drug in short supply since March, due to disruptions in supply from India-based manufacturer Intas Pharmaceuticals. Suppliers facing shortages include Accord Healthcare, Fresenius Kabi, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and Hikma Pharmaceuticals.

Portfolio Pulse from Vandana Singh

June 12, 2023 | 2:16 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.